Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,243
  • Shares Outstanding, K 21,773
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,590 K
  • EBIT $ -53 M
  • EBITDA $ -54 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.24

Options Overview Details

View History
  • Implied Volatility 167.43% (-190.23%)
  • Historical Volatility 70.83%
  • IV Percentile 40%
  • IV Rank 12.06%
  • IV High 357.66% on 02/17/26
  • IV Low 141.35% on 01/26/26
  • Expected Move (DTE 27) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 111
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 3.26
  • Today's Open Interest 281
  • Open Int (30-Day) 145
  • Expected Range 12.32 to 12.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.81
  • Number of Estimates 6
  • High Estimate -0.78
  • Low Estimate -0.87
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.14 +10.64%
on 02/05/26
16.60 -25.78%
on 01/22/26
-3.20 (-20.62%)
since 01/20/26
3-Month
8.82 +39.68%
on 11/21/25
16.60 -25.78%
on 01/22/26
+2.89 (+30.65%)
since 11/20/25
52-Week
4.88 +152.46%
on 04/09/25
17.94 -31.33%
on 10/08/25
-4.93 (-28.58%)
since 02/20/25

Most Recent Stories

More News
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Announces Leadership Appointments

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 12.32 (-0.73%)

Business Summary

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 13.04
2nd Resistance Point 12.76
1st Resistance Point 12.54
Last Price 12.32
1st Support Level 12.05
2nd Support Level 11.78
3rd Support Level 11.56

See More

52-Week High 17.94
Fibonacci 61.8% 12.95
Last Price 12.32
Fibonacci 50% 11.41
Fibonacci 38.2% 9.87
52-Week Low 4.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar